BUZZ-India's Dr Reddy's on course for second straight day of losses on semaglutide shipping disruption

** India's Dr Reddy's Laboratories REDY.NS down 2.6% to 1,228.6 rupees

** Stock on course for second straight day of losses, if trend holds

** Co reported on Thursday that supplies of generic semaglutide would remain unavailable in India and face disruptions in Canada due to impurities in active pharmaceutical ingredient, until late October at least

** Systematix downgrades REDY to "hold", believes execution risk remains, with possibility of further delays, if validation process takes longer than expected

** Emkay Global ("reduce", PT 1,300 rupees) cuts FY27 earnings estimates by 7% as prior margin assumptions "now seem out of reach"

** REDY rated "hold" on avg by 38 analysts; median PT is 1300 rupees - data compiled by LSEG

** Torrent Pharmaceuticals TORP.NS, which sources finished semaglutide doses from REDY, down 2.3%

** REDY down 3.4% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.